by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD
Although active surveillance may cause anxiety among patients, the treatment of asymptomatic, early-stage chronic lymphocytic leukemia (CLL) is not......READ MORE
by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD
Trends in the frontline treatment of chronic lymphocytic leukemia (CLL) include the widespread use of Bruton tyrosine kinase (BTK) inhibitor therap......READ MORE
by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD
The current approach to high-risk chronic lymphocytic leukemia (CLL) is characterized by continuous Bruton tyrosine kinase (BTK) inhibition in the ......READ MORE
by Jennifer R. Brown, MD, PhD; John C. Byrd, MD; and Susan O’Brien, MD
While the majority of patients initially diagnosed with chronic lymphocytic leukemia (CLL) do not require immediate treatment, mutational status ca......READ MORE
by John C. Byrd, MD; Ian W. Flinn, MD, PhD; and Jeff Sharman, MD
Chronic lymphocytic leukemia (CLL) treatment can impact quality of life (QOL) in many different ways. Psychological aspects of treatment may be imp......READ MORE
